Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NOSCAR

Financiado

Cerrado

decipheriNg Oncogenic SIgnalling patterns to break CAncer drug Resistance

Despite significant progress in drug therapies for breast cancer, about one fourth of patients still do not survive the disease. Modern, targeted therapies have been proposed to cure the more advanced and aggressive cases of breas... ver más

31/08/2023

UNIVERSITAET BERN

305K€

Presupuesto del proyecto: 305K€

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-08-31

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITAET BERN

304.72K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ImageMelTherapyLRI Single cell level intravital imaging of response tolerance... 231K€ Cerrado

TransPot Translational Research Network in Prostate Cancer 3M€ Cerrado

PI3K/SIGNAL-CANCER Roles of Class I PI 3 kinase isoforms in signalling and canc... 178K€ Cerrado

ROSETTA Deciphering the Role of aberrant glycOSylation in the rEspon... 176K€ Cerrado

CROC The natural K, Fe, and Cu isotopic response to Pt-based chem... 176K€ Cerrado

MODSIGN Modification of receptor tyrosine kinase signalling during t... 100K€ Cerrado

Duración del proyecto: 41 meses Fecha Inicio: 2020-03-18
Fecha Fin: 2023-08-31

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 305K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite significant progress in drug therapies for breast cancer, about one fourth of patients still do not survive the disease. Modern, targeted therapies have been proposed to cure the more advanced and aggressive cases of breast cancer. However, non-genetic and genetic mechanisms of drug resistance currently limit the promise of targeted therapy. NOSCAR aims to define the oncogenic Ras/Erk and PI3K/Akt signalling states relevant to breast cancer oncogenic mutations, and delineate the mechanisms which enable development of cancer resistance to targeted therapies. NOSCAR’s objectives are: Using a quantitative cell biology framework that combines a multiplexed biosensor system that reports on Erk/Akt dynamics at single cell level, computer vision, and statistical modelling, I will: (1) produce an atlas of single-cell Erk/Akt dynamic signalling patterns that are associated with a compendium of clinically-relevant breast cancer mutations; (2) measure the signalling states in cells perturbed with clinically-relevant drugs that target different components of the Ras/Erk and PI3K/Akt pathways to evaluate how the oncogenic signalling network is rewired by drug treatment; (3) measure signalling dynamics in 3D spheroid cultures and patient-derived organoids to explore how a self-organizing cellular ecosystem can spatially control signalling at the single cell level to locally control fate decisions, and how the latter process is compromised by an oncogenic mutation. This will provide new insights about tumor heterogeneity and signaling network structures that confer robustness against drug perturbations. We expect to identify vulnerabilities that might be efficiently targeted by drug combinations, providing new avenues to treat breast cancer. The planned research together with training and mentoring that I will receive thanks to the fellowship, will enable to successfully restart my career in research and will significantly benefit my further academic career prospects.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores